BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 8:54:00 PM | Browse: 815 | Download: 639
Publication Name World Journal of Gastroenterology
Manuscript ID 3865
Country/Territory Greece
2013-05-29 08:42
Peer-Review Started
2013-05-29 10:53
To Make the First Decision
2013-06-24 10:24
Return for Revision
2013-07-04 14:08
2013-07-07 04:00
Second Decision
2013-07-19 11:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-07-19 11:45
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-07-23 23:21
Typeset the Manuscript
2013-08-06 10:11
Publish the Manuscript Online
2013-08-19 18:22
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Review
Article Title Role of bevacizumab in colorectal cancer growth and its adverse effects: A review
Manuscript Source Invited Manuscript
All Author List Efstathios T Pavlidis and Theodoros E Pavlidis
Funding Agency and Grant Number
Corresponding Author Theodoros E Pavlidis, MD, PhD, Professor, Second Surgical Propedeutic Department, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Konstantinoupoleos 49, 54642 Thessaloniki, Greece. pavlidth@med.auth.gr
Key Words Angiogenesis; Vascular endothelial growth factor; Anti-angiogenic agents; Bevacizumab; Avastin; Cancer targeted therapy; Colorectal cancer
Core Tip Modern targeted therapy with anti-angiogenic agents is based on inhibition of angiogenesis, as the formation of new vessels is crucial for the growth and metastasis of malignant cells. Recent studies on the biological agent, bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor activity, have shown improved outcome in advanced colorectal cancer. The combination of irinotecan, capecitabine and bevacizumab is currently the most frequently used regime in the treatment of metastatic colorectal cancer with improved response rates. However, the rare side-effects of bevacizumab should always be considered.
Publish Date 2013-08-19 18:22
Citation Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: A review. World J Gastroenterol 2013; 19(31): 5051-5060
URL http://www.wjgnet.com/1007-9327/full/v19/i31/5051.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i31.5051
Full Article (PDF) WJG-19-5051.pdf
Manuscript File 3865-Review.doc
Answering Reviewers 3865-Answering reviewers.pdf
Copyright License Agreement 3865-Copyright assignment.pdf
Institutional Review Board Approval Form or Document BV in malignancy WJG.doc
Non-Native Speakers of English Editing Certificate 3865-Language certificate.pdf
Peer-review Report 3865-Peer reviews.pdf
Scientific Editor Work List 3865-Scientific editor work list.doc